Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...
Alligator Bioscience’s Annual Report 2018 published
Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience AB Year-end Report 2018
The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Alligator Bioscience AB Interim Report January-September 2018
The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator’s research and development. Significant even ...
Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...
Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...
Alligator Bioscience’s Annual Report 2017 published
Lund, Sweden, 22 March – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals f ...
Alligator Bioscience AB Full Year Report 2017
The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...
Alligator Bioscience AB Interim Report January-September 2017
Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...